Transcatheter Mitral Valve Implantation: TMVI Status in 2024

Abstract

Today, it is almost 22 years since the first transcatheter aortic valve implant (TAVI) and 11 years since the first transcatheter mitral valve implantation (TMVI) was implanted. TMVI never escalated like TAVI. So far, only one transcatheter mitral valve (TMV) has Conformité Européenne approval and none has Food and Drug Administration approval. This means that no TMV is commercial in the United States. There are several TMVs in clinical studies, but because of anatomical limitations, inclusion is slow. This editorial focuses on the challenges and opportunities in TMVI.

Keywords

• annulus
• cardiovascular medicine
• heart